Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest Update

by · The Cerbat Gem

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA – Get Free Report) was the target of a significant drop in short interest in December. As of December 15th, there was short interest totaling 100,401 shares, a drop of 40.4% from the November 30th total of 168,471 shares. Based on an average trading volume of 91,627 shares, the short-interest ratio is presently 1.1 days. Currently, 0.7% of the company’s stock are short sold. Currently, 0.7% of the company’s stock are short sold. Based on an average trading volume of 91,627 shares, the short-interest ratio is presently 1.1 days.

Genenta Science Trading Down 4.1%

NASDAQ:GNTA traded down $0.06 during trading hours on Monday, reaching $1.40. The company’s stock had a trading volume of 68,683 shares, compared to its average volume of 187,463. Genenta Science has a one year low of $1.28 and a one year high of $10.00. The business’s 50-day moving average is $2.15 and its 200-day moving average is $3.01.

Genenta Science (NASDAQ:GNTA – Get Free Report) last announced its quarterly earnings results on Friday, October 10th. The company reported ($0.10) earnings per share for the quarter. Analysts expect that Genenta Science will post -0.93 EPS for the current fiscal year.

Hedge Funds Weigh In On Genenta Science

An institutional investor recently bought a new position in Genenta Science stock. Citadel Advisors LLC acquired a new position in Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA – Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 12,486 shares of the company’s stock, valued at approximately $41,000. Citadel Advisors LLC owned about 0.07% of Genenta Science at the end of the most recent quarter. 15.13% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genenta Science in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Genenta Science currently has an average rating of “Sell”.

View Our Latest Analysis on Genenta Science

About Genenta Science

(Get Free Report)

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.

See Also